Golimumab in the treatment of extra-skeletal manifestations of ankylosing spondylitis
https://doi.org/10.14412/1996-7012-2019-4-110-115
Abstract
Extra-skeletal manifestations (EMs) of ankylosing spondylitis (AS) can occur and proceed in parallel with inflammatory changes in the joints and spine and often dominate in the clinical picture of AS, determining its high activity and significantly worsening the quality of life in patients. In a number of cases, EMs are characterized by an insufficient response to standard anti-inflammatory therapy for back pain, arthritis, and enthesitis; and there is a need to prescribe another class of drugs.
The review highlights the results of studies evaluating the efficacy of golimumab (GLM) in treating EMs in patients with AS: uveitis (GO-EASY Study) and ulcerative colitis (UC) (PURSUIT-SC, PURSUIT-M studies). Analysis of these studies have shown the high efficacy and safety of GLM in reducing the clinical manifestations of AS and in preventing the exacerbations of uveitis and UC. However, despite the successes achieved in treating AS and its EMs, there are many unresolved issues, including those related to the elaboration of optimal treatment regimens, which required longer observational studies with a large sample size.
About the Author
A. B. Demina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Anastasia Borisovna Demina
34A, Kashirskoe Shosse, Moscow 115522
References
1. Cruyssen B, Ribbens C, Boonen A, et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis. 2007 Aug;66(8):1072-7. doi: 10.1136/ard.2006.064543
2. Godzenko AA, Bochkova AG, Rumyantseva OA, et al. The frequency and severity of extraskeletal manifestations of ankylosing spondylitis. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2017;55(2):169-76. (In Russ.). doi: 10.14412/1995-4484-2017-169-176
3. Edmunds L, Elswood J, Calin A. New light on uveitis in ankylosing spondylitis. J Rheumatol. 1991 Jan;18(1):50-2.
4. Banares A, Hernandez-Garcia C, Fernandez-Gutierrez B, Jover JA. Eye involvement in the spondyloarthropathies. Rheum Dis Clin North Am. 1998 Nov;24(4): 771-84
5. Demina AB, Dubinina TV, Erdes ShF. HLA-B27-associated uveitis: From pathogenesis to therapy. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015;9(4):98-105. (In Russ.). Doi: 10.14412/1996-7012-2015-4-98-105
6. O'Rourke M, Haroon M, Alfarasy S, et al. The effect of anterior uveitis and previously undiagnosed spondyloarthritis: results from the DUET cohort. J Rheumatol. 2017 Sep; 44(9):1347-1354. doi: 10.3899/jrheum.170115. Epub 2017 Jul 1.
7. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008 Jul;67(7):955-9. Epub 2007 Oct 25.
8. Loh AR, Acharya NR. Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uveitis. Am J Ophthalmol. 2010 Oct;150(4): 534-542.e2. doi: 10.1016/j.ajo.2010.04.031.
9. Gritz DC, Schwaber EJ, Wong IG. Complications of uveitis: the Northern California Epidemiology of Uveitis Study. Ocul Immunol Inflamm. 2018;26(4):584-594. doi: 10.1080/09273948.2016.1247174. Epub 2017 Jan 23.
10. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderateto-severe ulcerative colitis. Gastroenterology. 2012 Feb;142(2):257-65.e1-3. doi: 10.1053/j.gastro.2011.10.032. Epub 2011 Nov 4.
11. Drozdova EA. Uveitis in rheumatic diseases: clinical features, diagnosis, immunopathogenesis and treatment. Diss. doct. med. sci. Ural'skaya gosudarstvennaya Akademiya Dopolnitel'nogo Obrazovaniya; 2006.]
12. Godzenko AA. Characteristics of clinical manifestations and treatment of uveitis in ankylosing spondylitis. Effektivnaya farmakoterapiya. Revmatologiya, travmatologiya i ortopediya. 2013;(2):26-35. (In Russ.).
13. Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015 Apr 18;(4):CD005468. doi: 10.1002/14651858.CD005468.pub2.
14. Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. 2006 Dec;65(12):1631-4. Epub 2006 Aug 10.
15. van Denderen JC, Visman IM, Nurmohamed MT, et al. Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis. J Rheumatol. 2014 Sep;41(9):1843-8. doi: 10.3899/jrheum.131289. Epub 2014 Aug 1.
16. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005 Aug;52(8):2447-51.
17. Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. 2006 Dec;65(12):1631-4. Epub 2006 Aug 10.
18. Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009 May; 68(5):696-701. doi: 10.1136/ard.2008.092585. Epub 2008 Jul 28.
19. van der Heijde D, Dougados M, Landewe R, et al. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology (Oxford). 2017 Sep 1;56(9):1498-1509. doi: 10.1093/rheumatology/kex174.
20. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007 Oct;56(10):3248-52.
21. Lie E, Lindström U, ZverkovaSandström T, et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann Rheum Dis. 2017 Sep;76(9):1515-1521. doi: 10.1136/annrheumdis-2016-210931. Epub 2017 Mar 2.
22. Wendling D, Joshi A, Reilly P, et al. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin. 2014 Dec;30(12):2515-21. doi: 10.1185/03007995.2014.969368. Epub 2014 Oct 8.
23. Wu D, Guo YY, Xu NN, et al. Efficacy of anti-tumor necrosis factor therapy for extraarticular manifestations in patients with ankylosing spondylitis: a meta-analysis. BMC Musculoskelet Disord. 2015 Feb 10;16:19. doi: 10.1186/s12891-015-0489-2.
24. van der Horst-Bruinsma IE, Nurmohamed MT. Management and evaluation of extra-articular manifestations in spondyloarthritis. Ther Adv Musculoskelet Dis. 2012 Dec;4(6):413-22. doi: 10.1177/1759720X12458372.
25. Sampaio-Barros PD, van der HorstBruinsma IE. Adverse effects of TNF inhibitors in SpA: are they different from RA? Best Pract Res Clin Rheumatol. 2014 Oct;28(5): 747-63. doi: 10.1016/j.berh.2014.10.001. Epub 2014 Oct 31.
26. Inman RD, Davis JC, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008 Nov;58(11):3402-12. doi: 10.1002/art.23969.
27. Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological drugs in the treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013. 549 p.].
28. Yazgan S, Celik U, Isik M, et al. Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis. Int Ophthalmol. 2017 Feb;37(1):139-145. doi: 10.1007/s10792-016-0239-y. Epub 2016 May 6.
29. Calvo-Rio V, Blanco R, Santos-Gomez M, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum. 2016 Aug; 46(1):95-101. doi: 10.1016/j.semarthrit.2016.03.002. Epub 2016 Mar 9.
30. Tosi GM, Sota J, Vitale A, et al. Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clin Exp Rheumatol. 2019 Jul–Aug; 37(4):680-683. Epub 2019 Apr 3.
31. Heslinga SC, Nurmohamed MT, Gerards AH, et al. Significantly reduced recurrence rate of acute anterior uveitis in ankylosing spondylitis during treatment with golimumab. Ann Rheum Dis. 2016;75 (Suppl 2):820.
32. Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2013 Jul;72(7):1149-55. doi: 10.1136/annrheumdis-2012-201933. Epub 2012 Aug 31.
33. Deodhar A, Yu D. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum. 2017 Dec;47(3):343-350. doi: 10.1016/j.semarthrit.2017.04.005. Epub 2017 Apr 25.
34. Stolwijk C, van Tubergen A, CastilloOrtiz JD, Boonen A. Prevalence of extraarticular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015 Jan; 74(1):65-73. doi: 10.1136/annrheumdis-2013-203582. Epub 2013 Sep 2.
35. Kawalec P, Pilc A. An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis. Arch Med Sci. 2016 Oct 1;12(5):1097-1109. Epub 2016 Mar 22.
36. Thorlund K, Druyts E, Toor K, et al. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs. Expert Rev Gastroenterol Hepatol. 2015 May;9(5):693-700. doi: 10.1586/17474124.2015.1024657. Epub 2015 Mar 12.
37. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan;146(1):85-95; quiz e14-5. doi: 10.1053/j.gastro.2013.05.048. Epub 2013 Jun 2.
38. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-tosevere ulcerative colitis. Gastroenterology. 2014 Jan;146(1):96-109.e1. doi: 10.1053/j.gastro.2013.06.010. Epub 2013 Jun 14.
39. Flamant M, Paul S, Roblin X. Golimumab for the treatment of ulcerative colitis. Expert Opin Biol Ther. 2017 Jul; 17(7): 879-886. Epub 2017 May 16.
Review
For citations:
Demina AB. Golimumab in the treatment of extra-skeletal manifestations of ankylosing spondylitis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2019;13(4):110-115. (In Russ.) https://doi.org/10.14412/1996-7012-2019-4-110-115
Views:
620
Email this article 